Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis. Emerging infectious diseases Puing, A. G., Epstein, D. J., Banaei, N., Subramanian, A. K., Liu, A. Y. 2021; 27 (10): 2734-2736

Abstract

Prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) prevents Pneumocystis jirovecii pneumonia and nocardiosis in immunocompromised patients but sometimes is avoided because of purported allergies or side effects. Of 25 immunocompromised patients receiving alternative prophylaxis in whom nocardiosis developed, 16 subsequently tolerated TMP/SMX treatment. Clinicians should consider TMP/SMX allergy evaluation and rechallenging to assess patient tolerance.

View details for DOI 10.3201/eid2710.210620

View details for PubMedID 34545802

View details for PubMedCentralID PMC8462344